PT-141
Research Use Only | Not for Human Consumption
A synthetic cyclic heptapeptide analog of alpha-MSH, supplied in lyophilized form.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. In preclinical research, it has been examined as an agonist of melanocortin receptors, with a focus on MC4R binding and downstream intracellular signaling in neuronal cell models.
| CAS# | Formula | Molar Mass |
|---|---|---|
| 189691-06-3 | C₅₀H₆₈N₁₄O₁₀ | 1025.2 g/mol |
All products are shipped in lyophilized form and must be reconstituted for in-vitro research applications. Refer to the Certificate of Analysis for purity and identity specifications.
A synthetic melanocortin receptor agonist peptide
What is PT-141?
PT-141, also called Bremelanotide, originated from Melanotan 2 research at the University of Arizona. Scientists there were characterizing melanocortin receptor analogs and observed MC4R-mediated signaling activity distinct from the melanogenesis pathways that were the original focus of investigation.
Researchers subsequently modified the Melanotan 2 structure to produce a cyclic heptapeptide with altered receptor selectivity. The resulting compound, PT-141, has since appeared in peer-reviewed preclinical and clinical publications examining melanocortin receptor binding and central nervous system signaling.
Bremelanotide has been the subject of published clinical pharmacology investigations. The research-grade form is used in melanocortin receptor signaling studies. This product is intended for research use only.
What is PT-141 studied for?
The following research areas represent documented studies available in the scientific literature. We make no claims regarding the benefits, efficacy, or therapeutic applications of this product.
Melanocortin Receptor Binding Research
In preclinical models, PT-141 has been investigated for its binding affinity and agonist activity at melanocortin-3 and melanocortin-4 receptors.
View Studies (1)MC4R Signaling Research
Laboratory studies have examined PT-141's interactions with central MC4R-expressing neurons and associated cAMP signaling cascades.
View Studies (1)Pharmacokinetic Research
Published investigations have characterized PT-141's pharmacokinetic parameters, including absorption, distribution, and plasma half-life in preclinical and clinical study populations.
View Studies (1)Hypothalamic Pathway Research
In preclinical rodent models, PT-141 has been examined for activity at melanocortin receptors expressed in the paraventricular nucleus and medial preoptic area.
View Studies (1)How should PT-141 be stored?
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability.
After reconstitution, the peptides will remain stable for up to 30 days.
Certificate of Analysis
All PT-141 batches are independently tested by a third-party laboratory for purity and identity verification via HPLC with UV detection coupled with Mass Spectrometry.
HPLC Purity
—
No Certificate of Analysis is available for the selected size yet. Contact support for batch-specific documentation.
COA documents are updated with each new batch. Contact support for batch-specific documentation.
Related Research Compounds
Frequently purchased with PT-141
Add all 3 items to your cart
$190
Clinical References
- Hallam TJ, et al. Melanocortins in the treatment of male and female sexual dysfunction. Current Topics in Medicinal Chemistry. 2007.
- Clayton AH, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder. Obstetrics & Gynecology. 2019.
- Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide. Journal of Sexual Medicine. 2006.
- Pfaus JG, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences. 2004.
